tissue microarray zl-brcsur180 (ZHUOLI IMAGING TECHNOLOGY CO LTD)
90
Structured Review
ZHUOLI IMAGING TECHNOLOGY CO LTD
tissue microarray zl-brcsur180
Tissue Microarray Zl Brcsur180, supplied by ZHUOLI IMAGING TECHNOLOGY CO LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+imager/tissue+microarray+zl+brcsur180/pmc11973456-92-1-7
Average 90 stars, based on 1 article reviews
Tissue Microarray Zl Brcsur180, supplied by ZHUOLI IMAGING TECHNOLOGY CO LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+imager/tissue+microarray+zl+brcsur180/pmc11973456-92-1-7
Average 90 stars, based on 1 article reviews
tissue microarray zl-brcsur180 - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4"
Article Title: Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4
Journal: Frontiers in Cell and Developmental Biology
doi: 10.3389/fcell.2025.1563353
Figure Legend Snippet: Screening of estrogen-regulated mRBPs in ER+ breast cancer. (a) , The schematic of iTRAQ quantitative proteomics. MCF-7 cells were treated with 10 nM estrogen for 48 h after 6 days of estrogen deprivation. (b) , Heat map representation of the 302 mRBP gene ratios (Treat/Control) in the iTRAQ quantitative proteomics. Each group represents three independent experiments. (c) , The heatmap plotted the relative expression levels of 612 mRBPs in tamoxifen-resistant(R) and parental(S) MCF-7 cells. (d) , Schematic diagram of 11 potential mRBPs in breast cancer. The left circle shows 100 proteins upregulated in quantitative proteomics. The right circle shows 100 genes upregulated in tamoxifen-resistant cells. (e) , Kaplan–Meier plots of RFS in breast cancer patients with different levels of FXR1 expression. (f) , Correlation analysis of FXR1 and ESR1 in TCGA ER+ breast cancer samples by GEPIA 2. (g, h) , Kaplan–Meier plots of RFS in ER+ (g) and ER- (h) patients with different levels of FXR1 expression. (i), Expression levels of FXR1, FMR1, and FXR2 in normal tissue (n = 291) and tumor tissue (n = 1,085) were analyzed by GEPIA 2. (j) , Protein levels of FXR1 in different cancers (tumor and normal samples). (k) , IHC staining of FXR1 of the representative patients in breast cancer tissue microarray. Scale bar: 500 μm (5✕), 100 μm (20✕). (l) , IHC H-scores of FXR1 in breast normal and tumor sections. (m) , IHC H-scores of FXR1 in ER+ and ER- breast tumor sections. Results are shown as mean ± S.D. *P < 0.05; **P < 0.01; ***P < 0.001; ns not significant (Unpaired two-tailed Student’s t test).
Techniques Used: Multiplex sample analysis, Quantitative Proteomics, Control, Expressing, Immunohistochemistry, Microarray, Two Tailed Test
Related Articles
Microarray:Article Title: Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4 Article Snippet: .. The |